logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: immunofluorescence
Load new posts () and activity
Like Reblog Comment
text 2019-10-01 13:51
Immunofluorescence Assay: An Emerging Market with Attractive Growth Opportunities

According to the new market research “Immunofluorescence Assay Market by Product (Reagent, Primary & Secondary Antibody, Kit, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The immunofluorescence assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%.

The global Immunofluorescence Assay market is segmented based on product, type, disease, end user and regions

 

On the basis of product, the reagents segment accounted for the largest share of the global immunofluorescence assay market. The large share of this segment is due to growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are driving the growth of the reagents segment.

 

Download a PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255585571

 

Browse and in-depth TOC on in “Immunofluorescence Assay Market " 
165 - Tables
34 - Figures 
192 - Pages 

Based on disease, the cancer segment accounted for the largest share of the immunofluorescence assay market. The large share of this segment can be attributed to the fact that the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study

 

Based on type, the immunofluorescence assay is segmented into direct and indirect immunofluorescence. The indirect immunofluorescence assay accounted for the major share of the immunofluorescence assay market. The advantages of indirect immunofluorescence technique such as its sensitivity, flexibility, better amplification of the signal, and lower cost—over direct immunofluorescence is the key factor increasing the adoption of this technique.

 

Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the immunofluorescence assay market. Factors contributing to its largest share include the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.

 

Request Free Sample Report @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=255585571

 

North America accounted for the largest share of the immunofluorescence assay market in 2017, followed by Europe and Asia Pacific. The rising incidence of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities, and the presence of key players in the region are the major factors responsible for the large share of North American immunofluorescence assay market.

 

Market Players

The key players in the Immunofluorescence Assay market are Thermo Fisher (US), Inova Diagnostics (US), and PerkinElmer (US) held the major share of the immunofluorescence assay market. Other major players operating in this market are Merck Millipore (US), Bio-Rad (US), Abcam (UK), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).

View Complete Press Release @ 
https://www.marketsandmarkets.com/PressReleases/immunofluorescence-assay.asp

Like Reblog Comment
text 2018-06-25 12:06
Immunofluorescence Analyzer Market Opportunity Analysis, 2018-2026

Immunoassays are biochemical tests that are used to quantify a specific substance or detect an analyte in body fluid sample or in the blood using an antibody or antigen. Immunoassays are highly specific due to the use of purified antigens and antibodies as reagents and it is sensitive. The common uses of immunoassay include hormones, measurement of drugs, tumor markers, markers of cardiac injury, and specific proteins. Immunofluorescence assays are different type of immunoassays. The advantages of a fluorescent detection system include higher sensitivity recognition of an analyte, simpler assay designs, and simplified reagents. Over the past few decades various advancements such as portability, compactness and real time monitoring of analyzer have supported the application of fluorescent-based immunoassay system in point-of-care.

Click To Continue Reading on Immunofluorescence Analyzer Market

A modern immunofluorescence assay-based analyzer uses a florescent compound that absorbs light energy at a specific wavelength and emits energy at a different wavelength. The difference between these light energy is called strokes shift. Immunofluorescence assay analyzers are extensively used in the field of clinical diagnostics, research and development, and quality control. Lack of skilled workforce and increasing test volume have led to the growth of immunofluorescence analyzer market size.

For instance, in 2016, AESKU group received clearance from the Food and Drug Administration (FDA) for its new HELIOS automated immunofluorescence system with AESKUSLIDES ANA HEp-2-Gamma assay. HELIOS is based upon automated system for the immunofluorescence processing with image recapturing with an integrated software and fluorescence microscope. In a single run, HELIOS can process and analyze patient samples. Over 300 HELIOS systems are used worldwide in clinical research in over 40 countries. Moreover, significance of care is now shifting towards early detection and prevention of diseases. Therefore, private companies are investing huge amount of capital for the development of rapid diagnostic testing solutions and low cost imaging technologies for point-of-care testing. For instance, in 2017, the Food and Drug Administration provided clearance to Quidel’s point-of-care Sofia® 2 immunoassay analyzer for use with Sofia influenza A+B assay. The next generation version, Sofia 2, is based on Quidel’s bestselling Sofia instrumented system. Sofia 2 is integrated with wireless connectivity and uses the florescent chemistry design with optics system to provide automated, accurate results in 3 minutes.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1794

Key Vendors:

Abbott Laboratories, bioMerieux, EMD Millipore, Siemens Healthcare, Thermo Fisher Scientific, and DiaSorin S.p.A.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
 #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

More posts
Your Dashboard view:
Need help?